{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Verve Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"VERV"},"Address":{"label":"Address","value":"500 TECHNOLOGY SQUARE,SUITE 901 SUITE 601, CAMBRIDGE, Massachusetts, 02139, United States"},"Phone":{"label":"Phone","value":"+1 617 603-0070"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States."},"CompanyUrl":{"label":"Company Url","value":"https://www.vervetx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Andrew D. Ashe","title":"President, COO & General Counsel"},{"name":"Andrew Sheely","title":"Vice President-Information Technology"},{"name":"Chelsey Jensen","title":"Director-Clinical Operations"},{"name":"Fred T. Fiedorek","title":"Chief Medical Officer"},{"name":"Jason Politi","title":"Chief Technical Operations Officer"},{"name":"Patrick Flight","title":"Senior Director-Medical Affairs"},{"name":"Richard Falzone","title":"Vice President-Clinical Operations"},{"name":"Sekar Kathiresan","title":"Chief Executive Officer & Director"},{"name":"Troy Lister","title":"Chief Scientific Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}